Company
The Aenova Group is a leading global contract manufacturer and development services provider for the pharmaceutical and healthcare industry. Our services include end-to-end manufacturing and development of all dosage forms and potency levels (ranging from nutraceuticals to high-potents) out of 15 sites in Europe and the US.
With our comprehensive know-how, many years of experience, well-trained staff of 4.500, innovative technologies and highest quality standards we are a reliable, long-term partner to pharmaceutical and consumer health care customers around the world, both in the human and veterinary healthcare market.
Milestones to a globally leading CDMO
2008
Foundation of Aenova Group
2008
2020 - 2022
Largest investment program in differentiated technologies/ innovation in corporate history
2020
- Expansion III Tittmoning solids (SOL)
- Gronau sterile ampoules expansion
2020
2019
- Complete overhaul of Feldkirchen semi-solids manufacturing site
- Extension of the soft gel site Cornu
2019
2018
Divestment of retail business EuroVital Pharma (EVP)
2018
Main corporate events
Main manufacturing/services events
Aenova was created 2008, as a merger of pharmaceutical companies Dragenopharm and Swiss Caps, forming the nucleus of the group. In 2012, the Temmler Group was acquired, and at the beginning of 2014 Haupt Pharma was acquired.
Since 2012, Aenova has been owned by the private equity company BC Partners.
